Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
Clinical trial NCT01279473 · COMPLETED
Trial details
- NCT number
- NCT01279473
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2005-08-01
- Primary completion
- 2009-12-01
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.